Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, based in the US, is focused on developing innovative therapies primarily for cancer and obesity, aiming to address critical unmet medical needs in these areas. Corbus Pharmaceuticals Holdings, Inc. is dedicated to the advancement of treatments for serious medical conditions. Founded in 2014 in Norwood, US, the company has engaged in only one deal as of September 2025, emphasizing its strategic focus on innovative drug development.

The company was founded by individuals with relevant industry experience, but specific details about their previous ventures are not available. Corbus Pharmaceuticals Holdings, Inc. specializes in developing innovative treatments primarily targeting cancer and obesity. The company’s leading product candidates include CRB-701, a Nectin-4 targeting antibody-drug conjugate designed for the treatment of various cancers, and CRB-913, a highly peripherally restricted CB1 inverse agonist aimed at obesity management.

These products are developed using advanced scientific research and aim to enhance patient outcomes significantly by addressing critical unmet medical needs within oncology and metabolic health. Corbus’s therapies are intended for healthcare providers, including hospitals, clinics, and specialized treatment centers, primarily in the United States and Europe, where they serve patients battling cancer and obesity. Corbus Pharmaceuticals operates on a revenue model that focuses on partnerships and collaborations with healthcare providers, biopharmaceutical companies, and research institutions. The company's transactions typically involve the licensing of its proprietary drug candidates to larger pharmaceutical entities for further clinical development and commercialization, or through direct sales of its products upon regulatory approval.

Revenue is generated from product sales, royalties, and potentially milestone payments associated with partnership agreements. The flagship products, including CRB-701, are expected to establish a pricing strategy reflective of their therapeutic value in the oncology market. Corbus’s approach to revenue generation is designed to support its ongoing commitment to advancing innovative treatment solutions while ensuring sustainable growth. Corbus Pharmaceuticals is actively working on expanding its product portfolio and market reach.

The company plans to launch new product candidates in the coming years, particularly focusing on its innovative therapies for cancer and obesity. In addition, Corbus aims to expand its geographical footprint, targeting both the US and European markets for broader distribution of its therapies. The recent funding round raised an undisclosed amount in September 2025, which will be utilized to support these initiatives and enhance the company’s capabilities in product development and market entry.